Siltuximab (Sylvant™)
IMPORTANT REMINDER
We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the Medical Policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.
POLICY
I. INDICATIONS
The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.
A. FDA-Approved Indication
Sylvant is indicated for the treatment of patients with multicentric Castleman’s disease who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
B. Compendial Use
1. Relapsed/refractory unicentric Castleman’s disease
2. CAR T-cell related toxicities - Cytokine release syndrome (CRS)
All other indications are considered experimental/investigational and not medically necessary.
II. DOCUMENTATION
Submission of the following information is necessary to initiate the prior authorization review: medical record documentation of HIV and HHV-8 status (where applicable).
III. CRITERIA FOR INITIAL APPROVAL
A. Multicentric Castleman’s disease or relapsed/refractory unicentric Castleman’s disease1,2
Authorization of 12 months may be granted for treatment of active multicentric Castleman’s disease with no organ failure or relapsed/refractory unicentric Castleman’s disease when both of the following criteria are met:
1. Member is human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
2. The requested medication is used as a single agent.
B. Cytokine release syndrome
Authorization of 1 month may be granted for treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome when either of the following criteria are met:
1. Cytokine release syndrome is refractory to high-dose corticosteroids and anti-IL-6 therapy.
2. The requested medication will be used as a replacement for the second dose of tocilizumab when supplies are limited or unavailable.
IV. CONTINUATION OF THERAPY
A. Multicentric Castleman’s disease or relapsed/refractory unicentric Castleman’s disease Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for multicentric and relapsed/refractory unicentric Castleman’s disease when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.
B. Cytokine release syndrome
All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.
APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS
BlueCross BlueShield of Tennessee’s Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.
ADDITIONAL INFORMATION
For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).
REFERENCES
1. Sylvant [package insert]. Hemel Hempstead, Hertfordshire, U.K.: EUSA Pharma, LTD; December 2019.
2. The NCCN Drugs & Biologics Compendium® © 2024 National Comprehensive Cancer Network, Inc. https://www.nccn.org. Accessed January 8, 2024.
ORIGINAL EFFECTIVE DATE: 6/14/2014
MOST RECENT REVIEW DATE: 8/13/2024
ID_CHS
Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.
This document has been classified as public information